Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337309 · ClinicalTrials.gov registry record · Phase 1
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
A Phase 1 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02337309: Clinical Trial Phase 1 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
NCT02337309 is a Phase 1 study that was terminated before completion, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02337309, a Phase 1 study, was terminated before completion, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. Funding Source - FDA OOPD
Primary Outcome
Toxicity will be graded using the CTCAE criteria, version 4. The CTCAE provides descriptive terminology and a grading scale for each adverse event listed. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov).
Interventions
- DRUG SF1126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07-09 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 1 |
Why NCT02337309 stopped before completion
NCT02337309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which SF1126 is the first listed.
NCT02337309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02337309 about?
NCT02337309 is a clinical study titled "SF1126 for Patients With Relapsed or Refractory Neuroblastoma". SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation d...
What is the current status of trial NCT02337309?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-07-09. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02337309?
The interventions under investigation include: SF1126 (DRUG).
Who is sponsoring clinical trial NCT02337309?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02337309's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI